# EDGAR Filing Document

**Accession Number:** 0001786766
**File Stem:** 0001628280-26-005243
**Filing Date:** 2026-2
**Character Count:** 5612
**Document Hash:** df20f1e5bc0f363fa93ffb15320208a5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-005243.hdr.sgml**: 20260203

**ACCESSION NUMBER**: 0001628280-26-005243

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260203

**FILED AS OF DATE**: 20260203

**DATE AS OF CHANGE**: 20260203

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Greco Michael V.
- **CENTRAL INDEX KEY:** 0001786766

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43097
- **FILM NUMBER:** 26595716

**MAIL ADDRESS:**
- **STREET 1:** C/O SPRINGWORKS THERAPEUTICS, INC.
- **STREET 2:** 100 WASHINGTON BLVD.
- **CITY:** STAMFORD
- **STATE:** CT
- **ZIP:** 06902
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Veradermics, Inc
- **CENTRAL INDEX KEY:** 0001827635
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 843304423
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 470 JAMES STREET
- **CITY:** NEW HAVEN
- **STATE:** CT
- **ZIP:** 06513
- **BUSINESS PHONE:** 228.372.3376

**MAIL ADDRESS:**
- **STREET 1:** 470 JAMES STREET
- **CITY:** NEW HAVEN
- **STATE:** CT
- **ZIP:** 06513

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VeraDermics, Inc
- **DATE OF NAME CHANGE:** 20201008

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Greco Michael V.<br><sub>(Last) (First) (Middle)</sub><br>C/O VERADERMICS, INCORPORATED<br>470 JAMES ST.<br><sub>(Street)</sub><br>NEW HAVEN, CT 06513<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Veradermics, Inc [ MANE ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-02-03 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_General Counsel_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | <sup>(1)</sup> | 2035-11-13 | Common Stock | 94273 | $12.19 | D |  |
| Stock Option (Right to Buy) | <sup>(2)</sup> | 2035-11-13 | Common Stock | 145140 | $12.79 | D |  |
| Stock Option (Right to Buy) | <sup>(3)</sup> | 2035-11-13 | Common Stock | 35912 | $12.79 | D |  |

---

### Footnotes:

(1) The option vests as to 25% of the underlying shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on July 21, 2026, the first anniversary of the vesting commencement date, and vests as to the remaining shares in equal monthly installments over 36 months thereafter, subject to continued service.

(2) The option will vest as to approximately 19% of the underlying shares of Common Stock as of June 21, 2026, and vests as to the remaining shares in equal monthly installments over 39 months thereafter, subject to continued service.

(3) This option shall be fully vested and exercisable upon the certification by the Issuer's board of directors (or compensation committee thereof) that the Issuer has achieved a market capitalization of $680.0 million prior to December 31, 2026, subject to the reporting person's continued service. Market capitalization will be measured as the trading price per share of the Issuer's Common Stock on its principal market national stock exchange multiplied by the number of the Issuer's shares of Common Stock issued and outstanding.

**Signature:** /s/ Michael Greco  
**Date:** 2026-02-03

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**